| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
DSPE-PEG-Amine does not have a specific biological receptor target. The amine group provides a reactive handle for bioconjugation to biomolecules containing amine-reactive groups (e.g., NHS esters, thiolates). It is used to functionalize liposomes and nanoparticles for drug targeting and surface modification.
|
|---|---|
| ln Vitro |
In vitro, DSPE-PEG-Amine is used in the synthesis of solid lipid and thermosensitive liposomal nanoparticles for the delivery of anticancer agents. The amine group enables diverse functionalities including drug targeting, surface modification, and bioconjugation. It can stably encapsulate or bind drug molecules, forming a drug carrier.
|
| ln Vivo |
In vivo, DSPE-PEG-Amine-containing liposomes and nanoparticles are used for drug delivery applications. The DSPE-PEG component has been FDA approved for medical applications. Surface modification with targeting ligands through the amine group can enhance targeted drug delivery.
|
| Enzyme Assay |
In vitro liposome functionalization involves incorporating DSPE-PEG-Amine into liposome formulations during preparation. The terminal amine group is then reacted with NHS-ester-activated targeting ligands (e.g., antibodies, peptides) or fluorescent probes. Conjugation efficiency is verified by gel electrophoresis, HPLC, or MALDI-TOF mass spectrometry.
|
| Cell Assay |
Cellular uptake and targeting efficacy of DSPE-PEG-Amine-functionalized nanoparticles are assessed in cell culture. Cells are treated with nanoparticles conjugated to targeting ligands or fluorescent markers via the amine group. Uptake is quantified by fluorescence microscopy, flow cytometry, or measuring the biological activity of encapsulated agents.
|
| Animal Protocol |
In vivo studies involve intravenous administration of DSPE-PEG-Amine-containing formulations in rodent models. Tissue distribution, pharmacokinetics, and therapeutic efficacy are evaluated. The DSPE-PEG component has been used in FDA-approved medical applications.
|
| ADME/Pharmacokinetics |
The PEG component improves solubility, stability, and circulation time. The amine group enables conjugation of targeting ligands, drugs, or imaging agents. Pharmacokinetic properties depend on the formulation and conjugated moieties. DSPE-PEG lipids have been used in FDA-approved drug delivery systems.
|
| Toxicity/Toxicokinetics |
DSPE-PEG-Amine is generally considered biocompatible. The DSPE-PEG component has been FDA approved for medical applications. Standard safety precautions for handling PEGylated lipids should be followed. No significant toxicity has been reported for the compound itself.
|
| References | |
| Additional Infomation |
DSPE-PEG-Amine (average MW 2000) is an amphiphilic polymer employed in the preparation of liposomes and nanoparticles. The amine group enables drug targeting, surface modification, and bioconjugation. It is commonly used for bioconjugation, coupling chemistries, and preparing functionalized delivery systems in drug delivery research. The molecular formula is (C2H4O)nC44H87N2O10P·NH3.
|
| Molecular Formula |
(C2H4O)NC44H87N2O10P.NH3
|
|---|---|
| Molecular Weight |
2000(Average)
|
| Exact Mass |
895.662
|
| CAS # |
474922-26-4
|
| PubChem CID |
156592378
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Rotatable Bond Count |
50
|
| Heavy Atom Count |
61
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNC(=O)OCCOCCN)OC(=O)CCCCCCCCCCCCCCCCC.N
|
| InChi Key |
AXHRCGLQEUQOIS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C46H91N2O11P.H3N/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-44(49)56-41-43(42-58-60(52,53)57-38-36-48-46(51)55-40-39-54-37-35-47)59-45(50)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h43H,3-42,47H2,1-2H3,(H,48,51)(H,52,53);1H3
|
| Chemical Name |
[3-[2-[2-(2-aminoethoxy)ethoxycarbonylamino]ethoxy-hydroxyphosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate;azane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: 16.67 mg/mL
DMSO: 7.14 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
